185 related articles for article (PubMed ID: 33244866)
1. Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
Luo M; Tian T; Zhang Y; Zhang X; Xie J; Xu J; Ren W; Tian C; Wang J; Tan Y; Wang H; Chen X
Int J Lab Hematol; 2021 Jun; 43(3):e110-e113. PubMed ID: 33244866
[No Abstract] [Full Text] [Related]
2. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
3. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of JAK2 mutations in myeloproliferative disorders.
Knoops L; Hermans C; Ferrant A; Constantinescu SN
Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
7. A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
Rumi E; Harutyunyan AS; Casetti I; Pietra D; Nivarthi H; Moriggl R; Cleary C; Bagienski K; Astori C; Bellini M; Berg T; Passamonti F; Kralovics R; Cazzola M
Am J Hematol; 2014 Jan; 89(1):117-8. PubMed ID: 24142793
[No Abstract] [Full Text] [Related]
8. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs.
Ormazábal C; Hurtado C; Aranaz P; Erquiaga I; García-Delgado M; Calasanz MJ; Novo FJ; Vizmanos JL
Leuk Res; 2008 Sep; 32(9):1485-7. PubMed ID: 18291525
[No Abstract] [Full Text] [Related]
9. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnostics of myeloproliferative neoplasms.
Langabeer SE; Andrikovics H; Asp J; Bellosillo B; Carillo S; Haslam K; Kjaer L; Lippert E; Mansier O; Oppliger Leibundgut E; Percy MJ; Porret N; Palmqvist L; Schwarz J; McMullin MF; Schnittger S; Pallisgaard N; Hermouet S;
Eur J Haematol; 2015 Oct; 95(4):270-9. PubMed ID: 25951317
[TBL] [Abstract][Full Text] [Related]
11. Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms?
Vorechovsky I; Jones AV; Cross NC
Leukemia; 2013 Sep; 27(9):1930-2. PubMed ID: 23511126
[No Abstract] [Full Text] [Related]
12. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
[TBL] [Abstract][Full Text] [Related]
13. Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.
Alghasham N; Alnouri Y; Abalkhail H; Khalil S
Int J Lab Hematol; 2016 Feb; 38(1):34-41. PubMed ID: 26361084
[TBL] [Abstract][Full Text] [Related]
14. [JAK2 mutation and thrombosis - recommendations for screening].
Held M
Dtsch Med Wochenschr; 2012 Feb; 137(5):227. PubMed ID: 22278696
[No Abstract] [Full Text] [Related]
15. A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders.
Albiero E; Bernardi M; Madeo D; Ruggeri M; Rodeghiero F
Am J Hematol; 2008 Jul; 83(7):603-4. PubMed ID: 18273905
[No Abstract] [Full Text] [Related]
16. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
[No Abstract] [Full Text] [Related]
17. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
[TBL] [Abstract][Full Text] [Related]
18. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.
Morotti A; Rocca S; Carrà G; Saglio G; Brancaccio M
Blood Rev; 2017 May; 31(3):139-150. PubMed ID: 27899218
[TBL] [Abstract][Full Text] [Related]
19. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
McCormick SR; Higgins RR; Grutkoski PS; Bousquet M; Quelen C; Bartholomaus LM; Brousset P
Br J Haematol; 2015 Apr; 169(2):290-3. PubMed ID: 25316507
[No Abstract] [Full Text] [Related]
[Next] [New Search]